Decheng entities sell BYSI across $3.23–$2.18; Fund III retains 1.98M shares
Rhea-AI Filing Summary
Decheng Capital-affiliated entities reported a series of open-market sales of BeyondSpring Inc. (BYSI) ordinary shares between 06/17/2025 and 08/04/2025. The Form 4 shows multiple dispositions totaling 394,436 shares sold across the reported dates at prices ranging from $3.23 down to $2.18. Footnotes note weighted-average prices and price ranges for specific blocks ($3.10–$3.34, $3.05–$3.27, $3.06–$3.19) and state the reporters will provide per-price details on request. Despite these sales, the filing shows that Decheng Capital China Life Sciences USD Fund III, L.P. continues to beneficially own 1,979,072 shares (indirect), and related Decheng entities and managers disclaim direct ownership except to the extent of pecuniary interest.
Positive
- Transparent disclosure of multiple open-market sales with transaction-level prices and footnotes offering per-price breakdowns upon request
- Continued indirect ownership: Decheng Capital China Life Sciences USD Fund III, L.P. retains 1,979,072 shares following reported sales
- Ownership structure and disclaimers are clearly stated, identifying general partners and the manager and their pecuniary-interest disclaimers
Negative
- Substantial insider dispositions: the filing documents 394,436 shares sold across the reporting period
- Declining sale prices over time in the table from $3.23 to $2.18, which may be viewed negatively by some market participants
Insights
TL;DR: Multiple open-market sales by Decheng funds totaling 394,436 BYSI shares across June–August, with prices falling from $3.23 to $2.18.
The reporting shows coordinated, incremental dispositions by affiliated Decheng funds and related entities rather than a single block trade. Transaction-level prices recorded in the table decline over the period, with weighted-average ranges disclosed for certain blocks. Material facts: 394,436 shares sold between 06/17/2025 and 08/04/2025; sale prices reported from $3.23 to $2.18. The filing also documents continued indirect beneficial ownership by Fund III of 1,979,072 shares. For investors, the filing is a clear disclosure of insider selling activity but does not state motives or off‑market agreements.
TL;DR: Decheng-related reporting persons disclosed multiple sales and included standard beneficial-ownership disclaimers; the filing is procedurally complete.
The Form 4 includes required explanatory footnotes describing ownership structure and disclaimers: general partners and the manager may be deemed beneficial owners but disclaim ownership except for pecuniary interest. The filing provides weighted-average price ranges and offers to provide per-price details on request, which supports compliance and transparency. The disclosures show sustained indirect holdings by affiliated funds while documenting significant disposition activity totaling 394,436 shares. This is a material disclosure of insider activity but contains no allegations of misconduct or additional governance actions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares | 2,196 | $2.18 | $5K |
| Sale | Ordinary Shares | 900 | $2.20 | $2K |
| Sale | Ordinary Shares | 20,572 | $2.19 | $45K |
| Sale | Ordinary Shares | 5,396 | $2.24 | $12K |
| Sale | Ordinary Shares | 2,152 | $2.28 | $5K |
| Sale | Ordinary Shares | 801 | $2.29 | $2K |
| Sale | Ordinary Shares | 246 | $2.29 | $563.34 |
| Sale | Ordinary Shares | 768 | $2.28 | $2K |
| Sale | Ordinary Shares | 252 | $2.27 | $572.04 |
| Sale | Ordinary Shares | 9,059 | $2.29 | $21K |
| Sale | Ordinary Shares | 324 | $2.42 | $784.08 |
| Sale | Ordinary Shares | 600 | $2.43 | $1K |
| Sale | Ordinary Shares | 1,700 | $3.09 | $5K |
| Sale | Ordinary Shares | 60,000 | $3.11 | $187K |
| Sale | Ordinary Shares | 225,217 | $3.16 | $712K |
| Sale | Ordinary Shares | 59,253 | $3.17 | $188K |
| Sale | Ordinary Shares | 5,000 | $3.23 | $16K |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (1)
- These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $3.10 to $3.34 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $3.05 to $3.27 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $3.06 to $3.19 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
